Bio Medica Laboratories IPO Closing Today 25 May 2026: GMP Rs 0, Indore Parenteral CDMO, Last Day to Apply

May 25, 2026
Posted by: Neeraj Pandey
Category: IPO

Bio Medica Laboratories IPO closes TODAY 25 May 2026 at 5 PM. GMP Rs 0. Price band Rs 132-139, NSE SME. Indore parenteral CDMO, GMP and GLP certified. Allotment 26 May, listing 29 May.

The Bio Medica Laboratories IPO closes TODAY (25 May 2026) at 5 PM on NSE SME. This is the LAST day to apply for the Rs 52.43 crore parenteral pharmaceutical CDMO IPO. The grey market premium stands at Rs 0 as of 25 May, indicating no listing gain expectation from grey market participants. Allotment is on 26 May 2026 (TOMORROW) and listing is on 29 May 2026 on NSE SME.

Table of Contents

Bio Medica Laboratories IPO Final Day Details

CLOSE DATE: TODAY 25 May 2026, LAST DAY. Apply before 5 PM.
Open Date: 21 May 2026
Allotment Date: 26 May 2026 (TOMORROW)
Share Credit: 27 May 2026
Listing Date: 29 May 2026 on NSE SME
Price Band: Rs 132 to Rs 139 per share
Issue Size: Rs 52.43 crore (Fresh 33,95,000 + OFS 3,77,000 = 37,72,000 total shares)
Face Value: Rs 10 per share
Lot Size: 1,000 shares
Minimum Retail: 2 lots = 2,000 shares = Rs 2,78,000
Category Split: QIB 50%, NII 15%, Retail 35%
Registrar: Skyline Financial Services Pvt. Ltd.
GMP: Rs 0 (nil), throughout subscription period

Track Bio Medica Laboratories IPO live on the .

About Bio Medica Laboratories: GMP and GLP Certified CDMO

Bio Medica Laboratories Limited, incorporated in August 2015 in Indore, Madhya Pradesh, is a pharmaceutical contract development and manufacturing organisation (CDMO) specialising in parenteral formulations. The company manufactures liquid injectables (LVP and SVP) and dry powder injectables for both human healthcare and veterinary segments on a B2B contract manufacturing basis. The facility is GMP-certified by the Madhya Pradesh FDA and GLP-certified. The company supplies finished pharmaceutical products to branded pharma companies across 11-plus Indian states.

Business: B2B CDMO, parenteral injectables (LVP/SVP), dry powder injectables, veterinary pharma
Certifications: GMP (MP FDA) + GLP certified
Presence: 11+ Indian states
Key use of proceeds: Rs 28.50 crore for new manufacturing unit (capacity expansion) + Rs 6.50 crore for debt repayment

Tap to Access Best Research Pieces on Univest

Track Bio Medica Laboratories IPO closing today live on Univest

FAQs on Bio Medica Laboratories IPO

Is today the last day to apply for Bio Medica Laboratories IPO?

Ans. Yes. Bio Medica Laboratories IPO closes TODAY, 25 May 2026, at 5 PM on NSE SME. Price band is Rs 132-139. Allotment is TOMORROW (26 May 2026). Listing is on 29 May 2026 on NSE SME. Minimum retail investment is Rs 2,78,000 (2,000 shares, 2 lots at Rs 139).

What is the Bio Medica Laboratories IPO GMP today?

Ans. Bio Medica Laboratories IPO GMP is Rs 0 (nil) as of 25 May 2026. No grey market premium established throughout the subscription period. This is a fundamental CDMO play, not a listing-gain trade. Allotment is tomorrow and listing is 29 May.

IPO IPO Closing Today

Author: Neeraj Pandey

Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.